{"id":"W1971185870","doi":"10.3747/co.20.1316","title":"Endocrine Therapy for Postmenopausal Women with Hormone Receptor–Positive her2–Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital du Saint-Sacrement; Dalhousie University; Queen Elizabeth II Health Sciences Centre; BC Cancer Agency; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Canada","keywords":"Exemestane; Medicine; Fulvestrant; Breast cancer; Oncology; Aromatase inhibitor; Internal medicine; Everolimus; Anastrozole; Clinical trial; Aromatase; Adjuvant therapy; Cancer; Tamoxifen; Gynecology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01816704,0.001058137,0.001708671,0.003144638,0.002591995,0.00239155,0.004427535,0.005622342,0.002368388],"category_scores_gemma":[0.01679068,0.000676831,0.002315678,0.003311702,0.002256724,0.001523506,0.002205227,0.007132637,0.0017217],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01681406,"about_ca_system_score_gemma":0.1158052,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.5077425,"about_ca_topic_score_gemma":0.6892055,"domain_scores_codex":[0.989883,0.001452483,0.001693032,0.0004429431,0.005650724,0.0008779319],"domain_scores_gemma":[0.9653148,0.003132546,0.002361969,0.0003776812,0.02515972,0.00365311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001282371,0.0001292056,0.002288681,0.005307019,0.0001344198,0.0003356904,0.0004078475,0.0004883111,0.001569391,0.002335485,0.7351786,0.251697],"study_design_scores_gemma":[0.0001195765,0.00007353823,0.006819855,0.007034471,0.0001666584,0.0004563011,0.0003515888,0.0002080391,0.0003740279,0.001225937,0.983089,0.00008101991],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.002391844,0.4149838,0.004511109,0.5264168,0.01731765,0.001837117,0.003750317,0.0001839121,0.02860748],"genre_scores_gemma":[0.03213304,0.7164133,0.03639444,0.1666313,0.01034208,0.001494916,0.009805327,0.0001523783,0.02663324],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.9831859,"threshold_uncertainty_score":0.9903129,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01548694589689443,"score_gpt":0.3280197203188384,"score_spread":0.312532774421944,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}